Details

Autor(en) / Beteiligte

• Mukonzo, Jackson
• Aklillu, Eleni
• Marconi, Vincent
• Schinazi, Raymond F.

Titel

Potential drug–drug interactions between antiretroviral therapy and treatment regimens for multi-drug resistant tuberculosis: Implications for HIV care of MDR-TB co-infected individuals

Ist Teil von

• International journal of infectious diseases, 2019-06, Vol.83, p.98-101

Ort / Verlag

Canada: Elsevier Ltd

Erscheinungsjahr

2019

Link zum Volltext

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• •MDR-TB agents exhibit overlapping enzyme inhibition that might affect ART outcomes.•Clofazimine, a core MDR-TB drug, could be responsible for most DDIs with ARVs.•Rifampicin enhances clofazimine against M. tuberculosis.•Rifampicin inductive effect may be important during MDR-TB HIV co-treatment.•Plausible biological explanations for MDR-TB and HIV drug–drug interactions exist. HIV-positive TB co-infected patients are at increased risk of multidrug-resistant (MDR)-TB compared to HIV-negative patients. Co-treatment of MDR-TB and HIV is common particularly in Sub-Saharan Africa where the co-morbidity is endemic. We discuss potential cellular metabolic pathway–mediated drug–drug interactions and the possible effect on HIV treatment outcomes of commonly prescribed antiretroviral therapy.